Press Releases

2025

Date	Title	Download Link
3/12/2025	Cannara Biotech to Present at The Ventum Canadian Cannabis Conference	Register
2/24/2025	Cannara Announces Extension of BMO Credit Facility and Convertible Debenture to Enhance Financial Flexibility and Support Execution of its Long-Term Strategy	View
01/27/2025	Cannara Biotech Reports Record Q1 2025 Revenue and National Market Share, Sets Stage for Continued Momentum in 2025

2024

Date	Title	Download Link
12/16/2024	Cannara Provides Update on Its 2024 Annual General Meeting Materials amid Canada Post Strike
12/12/2024	Cannara Biotech to Host Investor Webcast on Thursday December 19th, 2024
11/25/2024	Cannara Biotech Inc. Reports Q4 and Fiscal Year 2024 Results: Achieves Record Sales Growth and Operating Cash Flow
08/16/2024	Cannara Biotech Achieves its Highest National Market Share
07/23/2024	Cannara Biotech Reports Q3 2024 Financial Results
04/29/2024	Cannara Biotech Reports Q2 2024 Financial Results
01/30/2024	Cannara Biotech Announces Record-Breaking Q1 2024 Results: Continued Robust Growth and Market Expansion

2023

Date	Title	Download Link
12/13/2023	Cannara Biotech Announces Notice Of Annual General Meeting Of Shareholders To Be Held Virtually On January 25th, 2024
12/11/2023	Cannara Biotech to Host Investor Webcast on Thursday December 14th, 2023
12/7/2023	Cannara Biotech Reports Fourth Quarter and 2023 Fiscal Year Results: Record Growth and Profitability Continues
07/28/2023	Cannara Biotech Inc. Reports Record Q3 2023 Financial Results with Net Revenues of $15.9 Million and Net Income of $2.9 million
05/11/2023	Cannara Biotech Inc. To Participate At Canaccord Genuity’s 7th Annual Global Cannabis Conference
04/25/2023	Cannara Biotech Inc. to Host Investor Webcast on May 4th, 2023
04/24/2023	Cannara Biotech Inc. reports Q2 2023 Financial Results with quarterly net revenues of $13 million, a 76% increase compared to Q2 2022
02/10/2023	Cannara biotech inc. Announces results of annual shareholder meeting and conversion into equity of a $5m convertible debenture at $0.18 cent per common share
01/23/2023	Cannara Biotech Inc. Reports Q1 2023 Financial Results
01/12/2023	Cannara Announces Proposed Share Consolidation

2022

Date	Title	Download Link
11/30/2022	Cannara Announces Normal Course Issuer Bid for Common Shares of the Corporation
11/25/2022	Cannara Biotech Inc. Reports Record Q4 and 2022 Fiscal Year Financial Results
09/30/2022	Cannara Releases 14 New SKU’s Across Ontario and Quebec
09/20/2022	Cannara Biotech Inc. Announces Entry into the British Columbia Market and the Launch of its First Vape Cartridge and Vape Accessory, Tribal G Mint and UNI Pro Ark
09/01/2022	Acquisition of Common Shares of Cannara Biotech Inc.
08/10/2022	Cannara Biotech Inc. to Host Investor Webcast on August 17th, 2022
08/03/2022	Cannara signs an Exclusive Brand Partnership with Exotic Genetix in Canada
07/27/2022	Cannara Biotech Inc. Reports Fiscal Third Quarter 2022 Financial Results
06/01/2022	Cannara Biotech Inc. Closes $50 Million Credit Facility Led by BMO Commercial Banking
05/04/2022	Cannara Biotech Inc. to Present at Canaccord Genuity’s 6th Annual Cannabis Conference on May 11th and Retains Bristol Capital for Investor Relations Services
04/27/2022	Cannara Biotech Inc. Reports Fiscal Second Quarter 2022 Financial Results
01/20/2022	Cannara Biotech Inc. Reports Fiscal First Quarter 2022 Financial Results

2021

Date	Title	Download Link
12/08/2021	Cannara Biotech Inc. Reports Fourth Quarter and Fiscal Year 2021 Results
12/01/2021	Cannara Biotech Inc. upsizes CIBC Credit Facility to $22 Million
09/27/2021	Cannara’s Valleyfield Facility Receives Processing and Cultivation License
09/02/2021	Cannara Biotech Inc. Receives Amendment of its Licence from Health Canada Permitting the Sale of Cannabis 2.0 Products and Prepares for the Launch of its Hash Product Line in Quebec
07/28/2021	Cannara Biotech Inc. Reports Strong First Quarterly Profit Driven by Retail Debut
07/09/2021	Cannara Biotech Inc. Completes Additional $5 Million Private Placement
06/28/2021	Cannara Biotech Inc. Reports Preliminary Results Ahead of Third Quarter 2021
06/23/2021	Cannara Biotech Inc. Completes Acquisition of TGOD’s State-of-the-art Cultivation and Manufacturing Facility in Valleyfield, Quebec
06/10/2021	Cannara Biotech Inc. Enters into Definitive Agreement to Acquire TGOD’s State-of-the-Art Cultivation and Manufacturing Facility in Valleyfield, Quebec
04/28/2021	Cannara Biotech Delivers Strong Q2 2021 Results
04/07/2021	Cannara Biotech Commences Trading on TSXV on April 8, 2021
03/11/2021	Cannara Biotech Secures Conditional Approval to List on the TSX Exchange
02/25/2021	Cannara Biotech Launches Cannabis Brand Portfolio Now Available in Quebec – Tribal, Nugz, Orchid CBD
01/29/2021	Cannara Biotech Inc. Reports Q1 2021 Financial Results
01/08/2021	Cannara Biotech Receives Sales Licence from Health Canada

2020

Date	Title	Download Link
12/15/2020	Cannara Biotech Inc. (CSE: LOVE) announces Year-End and Q4 2020 Results
11/05/2020	Cannara Biotech Inc. Appoints Donald Olds to Board of Directors
07/27/2020	Cannara Biotech Inc. Reports Q3 2020 Financial Results
07/07/2020	Cannara Completes Acquisition of Global shopCBD.com
07/06/2020	Cannara enters LOI with SQDC for Entire First Year Production
05/27/2020	Cannara Proposes Agreement to Acquire Global shopCBD.com
05/15/2020	Cannara Biotech Inc. appoints Mary Durocher as New Board Director
04/20/2020	Cannara Harvests First Crop on 420
04/16/2020	Cannara Biotech Inc. Reports Q2 2020 Financial Results
02/20/2020	Cannara Insiders Form Buying Group to Fully Acquire FSD/FV Pharma’s Position in Cannara
01/31/2020	Cannara Biotech’s Farnham Facility Receives Cultivation Licence
01/20/2020	Cannara Biotech Reports Q1 2020 Financial Results

2019

Date	Title	Download Link
11/26/2019	Cannara Biotech Reports Q4 and Year-End 2019 Financial Results
10/10/2019	Cannara Biotech Secures $6 Million Mortgage Financing Facility with Canadian Imperial Bank of Commerce
07/12/2019	Cannara Biotech Announces Non-Brokered Private Placement of 12,000,000 Common Shares